4-step 4-h carboplatin desensitization protocol for patients with gynecological malignancies showing platinum hypersensitivity: a retrospective study

Naoto Takase, Koji Matsumoto, Takuma Onoe, Akihito Kitao, Maki Tanioka, Yoshitaka Kikukawa, Satoshi Yamaguchi, Kiyoshi Fujiwara, Shunichi Negoro

Research output: Contribution to journalArticlepeer-review

22 Citations (Scopus)


Background: Platinum agents are essential for treating gynecological malignancies, particularly ovarian cancer. However, multiple carboplatin doses may cause hypersensitivity reactions (HSRs). Carboplatin desensitization prevents life-threatening HSRs and promotes the successful completion of planned chemotherapy. Methods: Since January 2010, carboplatin desensitization was performed at our institution. Solutions with 1/1000, 1/100, and 1/10 dilutions of carboplatin and an undiluted solution were prepared in 250 mL of 5 % glucose. Each solution was administered as a 1-h intravenous infusion (4-step 4-h protocol). This retrospective analysis was approved by the institutional review board. Results: From January 2010 to December 2013, 20 patients with gynecological malignancies (median age 62 years, range 43–74 years) received desensitization treatment. The International Federation of Gynecology and Obstetrics stages at presentation were I, II, III, and IV in 1, 1, 15, 13 patients, respectively. During first-line and second-line treatments, 3 and 17 patients, respectively, experienced carboplatin-induced HSRs. The median carboplatin cycle number was 11 (range 2–16). In the first desensitization cycle, 17 (85 %) patients completed treatment without adverse events, 2 experienced Grade 1 HSRs but completed treatment, and 1 experienced Grade 3 HSR and discontinued treatment. The first desensitization cycle completion rate was 95 %. Of 83 desensitization cycles administered, 79 (95.2 %) were completed. No treatment-related deaths occurred. Conclusions: Most patients completed the planned chemotherapy. Our protocol could be conducted safely with shorter duration and simpler procedures than previous protocols. Carboplatin desensitization seems beneficial for patients with a history of carboplatin-induced HSRs; however, the risk of HSR recurrence still remains. Desensitization should therefore be performed only by well-trained staff.

Original languageEnglish
Pages (from-to)566-573
Number of pages8
JournalInternational Journal of Clinical Oncology
Issue number3
Publication statusPublished - Jun 11 2015
Externally publishedYes


  • Carboplatin
  • Desensitization
  • Gynecological malignancy
  • Hypersensitivity reaction
  • Ovarian cancer

ASJC Scopus subject areas

  • Surgery
  • Hematology
  • Oncology


Dive into the research topics of '4-step 4-h carboplatin desensitization protocol for patients with gynecological malignancies showing platinum hypersensitivity: a retrospective study'. Together they form a unique fingerprint.

Cite this